Latest Hairy cell leukemia Stories
WHITE PLAINS, N.Y., Dec.
Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options THOUSAND OAKS,
FDA Submission Reinforces Commitment to Addressing Significant Unmet Needs for Patients With Acute Lymphoblastic Leukemia, an Aggressive Cancer With Limited Treatment Options THOUSAND
Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced
SUNNYVALE, Calif., April 21, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer.
Discovering what they call the "Achilles' heel" for lymphoid leukemia, an international research team has tested a possible alternative treatment that eradicated the disease in mouse models.
A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.